A phase I trial of 2-methoxyestradiol (2ME2), (NSC-659853) an angiogenesis inhibitor, in patients with solid tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs 2-methoxyestradiol (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 30 Apr 2015 Biomarkers information updated
- 27 Sep 2005 New trial record.